Macaque trial advances development of pneumonia vaccine

OSAKA, Japan — The global impact of the coronavirus pandemic has sparked renewed attention on emerging and re-emerging infectious diseases. Researchers at Osaka Metropolitan University have made huge progress in the fight against pneumococcal pneumonia, one of the leading causes of respiratory death worldwide.

Despite the existence of vaccines against pneumococcal infections such as otitis media, sinusitis, and meningitis, the prevalence of pneumococcal pneumonia remains high. Currently, approximately 100 new Streptococcus pneumoniae serotypes have been identified, and the increase in pneumococcal infections caused by serotypes not covered by vaccines has become a matter of concern. This situation underscores the need for a more universal vaccine.

Building on their success in mucosal responses in 2019, the research group led by Professor Satoshi Uematsu developed a mucosal vaccine that induces antigen-specific mucosal immune responses, primarily immunoglobulin A (IgA), on the target mucosal surface. Associate Professor Kosuke Fujimoto of the Department of Immunology and Genomics, Osaka Metropolitan University Graduate School of Medicine, is working to narrow the gap in the effectiveness of pneumococcal pneumonia vaccination.

To successfully develop a new pneumococcal vaccine, the research team combined its proprietary mucosal vaccine technology with pneumococcal surface proteins that cover multiple serotypes. Experiments in mice and macaques demonstrated the vaccine’s efficacy in suppressing pneumococcal pneumonia in the target animal population.

“This research successfully developed a vaccine formulation that may be used in humans, which will advance the development of this vaccine for clinical applications,” said Professor Fujimoto. “This next-generation vaccine technology is expected to contribute to the treatment of infectious diseases in the future. .”

Their findings were published in the journal Inflammation and Regeneration.

/Public Release. Material from the original organization/author may be of a point-in-time nature and has been edited for clarity, style and length. Mirage.News does not adopt an institutional position or position, and all opinions, positions, and conclusions expressed in this article are solely those of the author. View the full article here.

Source link

Leave a Comment